Economy May 1, 2026 03:44 PM

WHO Member States Prolong Talks on Pathogen-Sharing Rules, Delaying Treaty Activation

Negotiations over the Pathogen Access and Benefit-Sharing annex continue, leaving the pandemic accord unable to take effect until PABS is resolved

By Avery Klein
WHO Member States Prolong Talks on Pathogen-Sharing Rules, Delaying Treaty Activation

World Health Organization member states have extended discussions on the Pathogen Access and Benefit-Sharing (PABS) annex, postponing the activation of the pandemic treaty adopted in May 2025. The talks aim to set procedures for rapid sharing of pathogen data and samples while securing fair access to resulting vaccines, tests and treatments. WHO Director-General Tedros Adhanom Ghebreyesus said progress has been made but urged continued urgency; the outcome will be presented to the World Health Assembly later in May.

Key Points

  • Member states extended negotiations on pathogen-sharing rules, postponing when the pandemic treaty from May 2025 can take effect - impacts public health policy and international regulatory frameworks.
  • Discussions center on the Pathogen Access and Benefit-Sharing (PABS) annex, which governs sharing of pathogen data and samples and aims to secure equitable access to vaccines, tests and treatments - relevant to healthcare, pharmaceutical and biotech sectors.
  • WHO Director-General Tedros Adhanom Ghebreyesus said progress has been made but urged urgency, noting the next pandemic is "a matter of when, not if"; the outcome will be reported to the World Health Assembly later in May.

World Health Organization member states announced on Friday that they will continue deliberations over rules governing the sharing of pathogens, extending talks that determine when a pandemic treaty adopted in May 2025 can come into force. The extension leaves the accord's activation contingent on further agreement.

The central focus of the negotiations is the Pathogen Access and Benefit-Sharing annex - referred to as PABS - which sets out how countries should share data and samples of pathogens that could pose public health risks. The annex is designed to accompany the central treaty by establishing procedures intended to guarantee that countries supply potentially pandemic-causing biological material rapidly while also creating mechanisms to promote equitable access to vaccines, tests and treatments developed from those materials.

Under the terms agreed by member states, the pandemic accord cannot take effect until the PABS annex is finalized. The treaty was developed to strengthen the global response to future pandemics following the COVID-19 pandemic, and PABS is a required component for its implementation.

WHO Director-General Tedros Adhanom Ghebreyesus said that negotiators had made progress but called on countries to continue working with urgency. He emphasized the continued risk of another pandemic by saying the next pandemic is "a matter of when, not if."

The extended talks will reach a conclusion whose outcome is scheduled to be presented to the World Health Assembly later in May. Until member states arrive at consensus on PABS, the broader pandemic accord remains unable to enter into force.

This development sustains uncertainty about the timeline for an operational international framework to govern pathogen sharing and benefit distribution. The continued negotiations underscore the diplomatic and technical work still required to finalize the annex before the accord can be activated.


Summary

WHO member states have prolonged negotiations on the Pathogen Access and Benefit-Sharing annex, delaying the activation of the pandemic treaty adopted in May 2025. The PABS annex governs how pathogen data and samples are shared and seeks to ensure equitable access to medical countermeasures. The WHO director-general noted progress but urged urgent continued work; the outcome will be presented to the World Health Assembly later in May.

Risks

  • Delay in finalizing PABS creates uncertainty over when the pandemic accord can be activated, affecting timelines for coordinated global responses - this uncertainty touches public health planning and sectors involved in medical countermeasure development.
  • Until agreement on PABS is reached, questions remain about mechanisms to ensure equitable access to vaccines, tests and treatments derived from shared pathogens - this presents uncertainty for pharmaceutical and biotech firms and for public health procurement.
  • Extended negotiations sustain policy and regulatory uncertainty, which could affect preparedness efforts and decisions by governments and health institutions while discussions continue - these uncertainties influence markets tied to health infrastructure and vaccine supply chains.

More from Economy

Yen Holds Near Two-Month High as Dollar Strengthens on Middle East Tensions May 4, 2026 Venezuela’s Monthly Inflation Falls to 10.6% in April, Central Bank Reports May 4, 2026 Customs Agency Says First Electronic Refunds for Trump's Tariffs Could Begin May 12 May 4, 2026 Iran's Araghchi Says Military Action Won't Resolve Hormuz Standoff, Voices Cautious Hope on Pakistan-Brokered Talks May 4, 2026 Westpac’s H1 profit underperforms as margins and credit charges weigh May 4, 2026